Sanofi Stock Euronext Paris
Stocks
SANNV
FR001400ED05
Pharmaceuticals
OTC Markets Traded| Market Cap | 84.84B 95.48B 79.18B 72.17B 136B 9,179B 137B 958B 371B 4,692B 358B 351B 15,060B | P/E 2026 * |
11.3x | P/E 2027 * | 9.81x |
|---|---|---|---|---|---|
| Enterprise Value | 96.74B 109B 90.29B 82.3B 155B 10,467B 157B 1,093B 423B 5,351B 409B 400B 17,173B | EV / Sales 2026 * |
2.03x | EV / Sales 2027 * | 1.85x |
| Free-Float |
88.34% | Yield 2026 * |
6.01% | Yield 2027 * | 6.35% |
Last Transcript: Sanofi
| 1 day | -1.59% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/05/2026 | |
| Director of Finance/CFO | 64 | 01/04/2024 | |
Paulo Fontoura
CTO | Chief Tech/Sci/R&D Officer | - | 01/09/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 30/04/2019 | |
Rachel Duan
BRD | Director/Board Member | 56 | 28/04/2020 |
Lise Kingo
BRD | Director/Board Member | 65 | 28/04/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.59% | -7.74% | - | - | 95.48B | |
| -0.61% | -3.43% | +36.07% | +117.61% | 1,019B | |
| -1.02% | -5.60% | +35.72% | +64.82% | 617B | |
| +1.11% | -0.58% | +12.36% | +78.27% | 464B | |
| +0.34% | -3.01% | +61.79% | +41.79% | 356B | |
| -0.95% | -4.05% | +20.54% | +40.33% | 333B | |
| -1.46% | -2.89% | +10.57% | +26.54% | 267B | |
| -1.35% | -5.43% | -6.17% | +8.82% | 244B | |
| -1.04% | -2.79% | +35.30% | +54.42% | 218B | |
| -1.87% | -4.10% | +28.44% | +97.54% | 179B | |
| Average | -0.84% | -3.39% | +26.07% | +58.90% | 410.8B | |
| Weighted average by Cap. | -0.62% | -3.33% | +29.07% | +71.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.66B 53.64B 44.49B 40.55B 76.47B 5,157B 77.18B 538B 209B 2,636B 201B 197B 8,461B | 50.62B 56.98B 47.25B 43.07B 81.22B 5,477B 81.98B 572B 222B 2,800B 214B 209B 8,986B |
| Net income | 7.48B 8.42B 6.98B 6.37B 12.01B 810B 12.12B 84.53B 32.75B 414B 31.62B 30.94B 1,328B | 8.9B 10.02B 8.31B 7.57B 14.29B 963B 14.42B 101B 38.97B 493B 37.63B 36.81B 1,581B |
| Net Debt | 11.91B 13.4B 11.11B 10.13B 19.11B 1,288B 19.28B 135B 52.12B 659B 50.32B 49.23B 2,114B | 8.61B 9.69B 8.04B 7.33B 13.82B 932B 13.95B 97.28B 37.7B 476B 36.39B 35.6B 1,529B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
